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OBJECTIVE—Insulin represses the expression of gluconeo-
genic genes at the mRNA level, but the hormone appears to have
only weak inhibitory effects in vivo. The aims of this study were
1) to determine the maximal physiologic effect of insulin, 2)t o
determine the relative importance of its effects on gluconeogenic
regulatory sites, and 3) to correlate those changes with alter-
ations at the cellular level.
RESEARCH DESIGN AND METHODS—Conscious 60-h
fasted canines were studied at three insulin levels (near basal,
4,o r1 6 ) during a 5-h euglycemic clamp. Pancreatic hormones
were controlled using somatostatin with portal insulin and
glucagon infusions. Glucose metabolism was assessed using the
arteriovenous difference technique, and molecular signals were
assessed.
RESULTS—Insulin reduced gluconeogenic ﬂux to glucose-6-
phosphate (G6P) but only at the near-maximal physiological level
(16 basal). The effect was modest compared with its inhibitory
effect on net hepatic glycogenolysis, occurred within 30 min, and
was associated with a marked decrease in hepatic fat oxidation,
increased liver fructose 2,6-bisphosphate level, and reductions in
lactate, glycerol, and amino acid extraction. No further diminu-
tion in gluconeogenic ﬂux to G6P occurred over the remaining
4.5 h of the study, despite a marked decrease in PEPCK content,
suggesting poor control strength for this enzyme in gluconeo-
genic regulation in canines.
CONCLUSIONS—Gluconeogenic ﬂux can be rapidly inhibited
by high insulin levels in canines. Initially decreased hepatic
lactate extraction is important, and later reduced gluconeogenic
precursor availability plays a role. Changes in PEPCK appear to
have little or no acute effect on gluconeogenic ﬂux. Diabetes 58:
2766–2775, 2009
H
epatic glycogen metabolism in vivo is ex-
tremely sensitive to the effects of insulin. In the
healthy state, small increases (twofold) in the
plasma insulin level can result in near-complete
inhibition of the net contribution of glycogen to hepatic
glucose production (HGP) (1). This effect has been as-
cribed to activation of glycogen synthesis (2). On the other
hand, the effects of insulin on hepatic gluconeogenesis are
less potent, are more complex, and occur through multiple
mechanisms. The direct inhibitory effect of insulin on the
transcription and activity of key hepatic gluconeogenic
enzymes through forkhead box class O-1 (FOXO1) phos-
phorylation, including phosphoenolpyruvate carboxyki-
nase (PEPCK) (3,4), is well established. Further, insulin
inhibits the secretion of glucagon, a known activator of
gluconeogenesis (5), thereby bringing about an indirect
inhibitory effect on the process in the liver. In addition,
insulin inhibits lipolysis (6), which reduces circulating
glycerol and nonesteriﬁed free fatty acid (NEFA) levels.
Glycerol is an important gluconeogenic (GNG) precursor,
and NEFAs provide energy for gluconeogenesis (7). Net
hepatic lactate uptake is reduced by insulin through
several mechanisms. First, the hormone inﬂuences sub-
strate cycling through the glycolytic/GNG pathways via
allosteric and phosphorylation-mediated changes in the
activity of key enzymes (e.g., bifunctional enzyme and
pyruvate kinase) (4,8). Second, hepatic lactate ﬂux is
regulated by insulin secondary to its inhibitory effect on
lipolysis (e.g., via reduced citrate, which results in in-
creased phosphofructokinase-1 [PFK-1] activity) (4,8,9).
Insulin decreases net amino acid release from muscle via
inhibition of proteolysis and potentially by increased pro-
tein synthesis (10), although the effect of reduced GNG
amino acid precursor availability is offset to some degree
by an increase in hepatic amino acid transport (11).
Finally, evidence in rodents suggests that hepatic glucone-
ogenesis may also be inhibited as the result of insulin
action in the hypothalamus. It is postulated that brain
insulin action increases vagal transmission, thereby in-
creasing the phosphorylation of signal transducer and
activator of transcription 3 (STAT3) in the liver and in turn
reducing PEPCK and glucose-6-phosphatase (G6Pase)
transcription (12–14).
Assessment of gluconeogenesis in vivo is complicated
by the sensitive effects of insulin on hepatic glycogen
metabolism. Because higher insulin concentrations are
required to suppress gluconeogenesis than to inhibit gly-
cogenolysis or increase glycogen synthesis (15,16), glu-
coneogenically derived glucose-6-phosphate (G6P) can be
diverted into hepatic glycogen even during mild hyperin-
sulinemia. As a result, redirection of the product of GNG
ﬂux into hepatic glycogen can decrease gluconeogenesis,
per se, in the absence of a fall in GNG ﬂux to G6P (1,17).
Despite the numerous mechanisms by which insulin can
inhibit the GNG process, acute physiologic increases in
insulin have minimal impact on GNG ﬂux in humans and
large animals (1,15,17–20). Much of what is known about
the regulation of gluconeogenesis is derived from in vitro
studies on tissues or cells that lack important inputs for
GNG control (e.g., GNG precursor load, NEFA availability,
neuronal transmission, glycogen, hormonal milieu). Like-
wise, many studies of GNG regulation have been per-
formed in rodents, and it is not clear how control of the
process may differ in those species compared with larger
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times higher in rats and mice than in humans or canines;
glycogen stores are completely depleted during fasting in
rodents but not in humans or canines).
Given the difﬁculty in detecting an inhibitory effect of
insulin on GNG ﬂux in vivo, conditions were optimized in
the present study to allow such an effect to be seen. First,
canines were fasted for 60 h to increase the percentage
contribution of gluconeogenesis to HGP. In addition, be-
cause we previously failed to observe any suppression of
GNG ﬂux in overnight fasted canines when the level of
insulin was increased 4-fold (20), we examined both 4- and
16-fold increases in insulin. Finally, insulin was elevated
f o r5ht oprovide sufﬁcient time for changes in insulin
signaling to affect gene transcription and for the latter to
translate into substantial effects on GNG enzyme levels
and activities. To focus on the effects of insulin, glucagon
and glucose were clamped at basal levels. In addition, liver
biopsies were taken at the end of each study to allow the
effects of insulin on molecular signaling and gene tran-
scription to be correlated with alterations in whole-body
metabolic ﬂux rates.
RESEARCH DESIGN AND METHODS
Animal care and surgical procedures. Sixteen conscious mongrel canines
of either sex were studied after a 60-h fast. Housing and diet have been
described previously (1). The surgical facility met the standards published by
the American Association for the Accreditation of Laboratory Animal Care,
and the protocols were approved by the Vanderbilt University Medical Center
Animal Care Committee. All canines underwent a laparotomy 2 weeks before
the experiment to implant portal vein infusion catheters into the jejunal and
splenic veins, sampling catheters into the femoral artery and portal and
hepatic veins, and ultrasonic ﬂow probes (Transonic Systems, Ithaca, NY)
around the hepatic artery and portal vein, as described elsewhere (1). All
canines studied were healthy, as indicated by 1) leukocyte count 18,000/
mm
3, 2) hematocrit 35%, and 3) good appetite and normal stools.
Experimental design. Animals were allowed to rest quietly in a Pavlov
harness for 60 min before the experiments started. Each study consisted of a
basal period (40 to 0 min) and an experimental period (0–300 min).
Somatostatin (0.8 g  kg
1  min
1; Bachem, Torrance, CA) was infused
(0–300 min) to inhibit endogenous pancreatic hormone secretion. During the
same period, intraportal infusions of glucagon (0.5 ng  kg
1  min
1; Lilly,
Indianapolis, IN) and insulin (300, 1,200, or 5,000 U  kg
1  min
1; Lilly) were
given in the control (n  5), 4 (n  5), or 16 (n  6) groups, respectively.
Previously, when the plasma glucose level was maintained at basal levels by
titration of intraportal insulin in 60-h fasted canines, the insulin requirement
was 215  24 U  kg
1  min
1 (21). Therefore, in the present study, insulin
was infused in the control group at a rate slightly above basal. Glucose was
infused intravenously to maintain euglycemia.
Immediately after the ﬁnal sampling time, each animal was anesthetized
and three sections of liver lobes were freeze clamped in situ and stored at
70°C as previously described (1). All animals were then killed, and the
correct positions of the catheter tips were conﬁrmed.
Analytical procedures. Hematocrit; plasma glucose, glucagon, insulin, cor-
tisol, and NEFA; and blood alanine, glycine, serine, threonine, lactate,
glutamine, glutamate, glycerol, and -hydroxybutyrate concentrations
were determined as previously described (1). RNA extraction, cDNA
synthesis, real-time PCR, SDS-PAGE, and Western blotting procedures
were performed by standard methods, details of which are provided in the
online appendix at http://diabetes.diabetesjournals.org/content/suppl/2009/
08/ 25/db09-0328.DC1/DB09-0328_online_appendix.pdf. Fructose 2,6-
bisphosphate (F2,6P2) levels and pyruvate kinase activity were determined
as described in the online appendix.
Calculations. Net hepatic substrate balances were calculated with the
arteriovenous (A-V) difference method using the following formula: net
hepatic balance  loadout – loadin, where loadout  [H]  HF and loadin  [A]
 AF 	 [P]  PF and where [H], [A], and [P] are the substrate concentrations
in hepatic vein, femoral artery, and portal vein blood or plasma, respectively,
and HF, AF, and PF are the blood or plasma ﬂow in the hepatic vein, hepatic
artery, and portal vein, respectively, as determined by the ultrasonic ﬂow
probes. With this calculation, a positive value represents net output by the
liver, whereas a negative value represents net hepatic uptake. Plasma glucose
values were multiplied by 0.73 to convert them to blood glucose values as
validated elsewhere (20). Net hepatic fractional extraction was calculated by
dividing net hepatic substrate balance by hepatic substrate load. Nonhepatic
glucose uptake was calculated as the glucose infusion rate plus net hepatic
glucose balance, with changes in the glucose mass accounted for when
deviations from steady state were present. The approximate insulin and
glucagon levels in plasma entering the liver sinusoids were calculated using
the formula [A]  %AF 	 [P]  %PF, where [A] and [P] are arterial and portal
vein hormone concentrations, respectively, and %AF and %PF are the respec-
tive fractional contributions of arterial and portal ﬂow to total hepatic blood
ﬂow.
Gluconeogenesis is the synthesis and subsequent hepatic release of glu-
cose from noncarbohydrate precursors. Because carbon produced from ﬂux
through the GNG pathway can also be stored in glycogen, we make a
distinction between gluconeogenesis and GNG ﬂux to G6P. Hepatic GNG ﬂux
to G6P was determined by summing net hepatic uptake rates of GNG
precursors (alanine, glycine, serine, threonine, glutamine, glutamate, glycerol,
lactate, and pyruvate); these rates were divided by two to account for the
incorporation of three carbon precursors into the six-carbon glucose mole-
cule. Glycolytic ﬂux was estimated by summing the net hepatic output rates
(when such occurred) of the substrates noted above (in glucose equivalents)
and hepatic glucose oxidation. In earlier studies, glucose oxidation was 0.2 
0.1 mg  kg
1  min
1 even when the concentrations of circulating insulin,
glucose, and NEFAs varied widely (22,23). Because glucose oxidation did not
change appreciably under conditions similar to the present study, glucose
oxidation was assumed to be constant (0.2 mg  kg
1  min
1). Net hepatic
glycogenolytic ﬂux was estimated by subtracting GNG ﬂux from the sum of
net hepatic glucose balance and glycolytic ﬂux. A positive number therefore
represents net glycogen breakdown, whereas a negative number indicates net
glycogen synthesis.
The assumptions related to using the A-V difference technique for assessing
GNG ﬂux to G6P should be considered. Ideally, GNG ﬂux would be calculated
using unidirectional hepatic uptake and output rates for each substrate, but
this would be difﬁcult because it would require the simultaneous use of
multiple stable isotopes that could themselves induce a mild perturbation of
the metabolic state; therefore, net hepatic balance was used instead. There is
little or no production of GNG amino acids or glycerol by the liver, so in this
case the compromise is of little consequence. This may not be the case for
lactate, however. The estimate of GNG ﬂux to G6P will be quantitatively
accurate only if lactate ﬂux is unidirectional at a given moment (i.e., either in
or out of the liver). In a given cell, this is a reasonable assumption in light of
the reciprocal control of gluconeogenesis and glycolysis (4). Spatial separa-
tion of metabolic pathways may exist, however, so that predominantly GNG
periportal and glycolytic perivenous hepatocytes (24) could simultaneously
take up and release lactate, respectively. Total GNG ﬂux will be underesti-
mated to the extent that this occurs and to the extent that intrahepatic
precursors (GNG amino acids) contribute to the process. The method also
assumes that there is 100% conversion of GNG precursors taken up by the
liver into G6P (they are not oxidized or used in the synthesis of proteins or
fatty acids). The errors due to these assumptions are difﬁcult to assess but
appear to be small and in fact are offsetting. Results obtained using the A-V
difference technique described here were previously compared with results
obtained with independent GNG measurements that are not subject to these
assumptions, and they were similar (1,25), suggesting that these assumptions
appear reasonable.
It should be noted that our estimates of gluconeogenesis and glycogenol-
ysis relate solely to the liver. In a previous study, net renal glucose balance
was close to zero in 60-h fasted canines, indicating that in a net sense the liver
is the only source of glucose in such animals (21). To the extent that the
kidney makes an absolute contribution to whole-body glucose production, we
would slightly underestimate whole-body GNG ﬂux.
Statistical analysis. Statistical comparisons were carried out using two-way
repeated measure ANOVA (group  time) (SigmaStat). One-way ANOVA
comparison tests were used post hoc when signiﬁcant F ratios were obtained.
Signiﬁcance was determined as P  0.05.
RESULTS
Hormone levels. Plasma insulin levels did not increase
appreciably in the control group, whereas they increased
an average of 4- and 16-fold in the 4 and 16 groups,
respectively (Fig. 1). The plasma arterial and hepatic
sinusoidal glucagon and arterial cortisol levels remained
basal and were similar over time and between groups (not
shown).
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play a role in the regulation of hepatic gluconeogenesis in
vivo, as does the load of glycerol reaching the liver. In the
control group, the arterial plasma NEFA level fell by 
25%
during the experimental period, whereas the glycerol level
did not change signiﬁcantly (2
10%; Table 1). There was
a rapid fall in the arterial NEFA levels in the 4 and 16
groups (reduced by 58 and 75%, respectively, at 30 min;
285 and 94%, respectively, during the last hour). Glycerol
levels also decreased in the hyperinsulinemic groups (245
and 43% at 30 min, respectively; 240 and 65%, respec-
tively, during the last hour). These changes indicate rapid
inhibition of lipolysis and increased re-esteriﬁcation of
fatty acids. In the control group, net hepatic NEFA uptake
tended to decrease slowly over time (230% by the last
hour), whereas in the 4 and 16 groups, net hepatic
NEFA uptake decreased quickly (261 and 81%, respec-
tively, at 30 min) and was markedly reduced (285 and
95%, respectively) by the last hour of the study (Table 1).
Hepatic NEFA oxidation was also reduced by hyperinsu-
linemia, as indicated by marked reductions in -hydroxy-
butyrate production in both hyperinsulinemic groups
(Table 1).
GNG precursor availability and hepatic uptake. Lac-
tate, glycerol, and alanine make the greatest quantitative
contributions to GNG ﬂux to G6P (52, 12, and 20%,
respectively, during the basal state), with the other amino
acids accounting for the remainder. In the control group,
there were no changes in the level, net hepatic fractional
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FIG. 1. Arterial and hepatic sinusoidal plasma insulin and glucagon in
60-h fasted conscious canines during the basal (40 to 0 min) and
experimental (0–300 min) periods (means  SEM; n  5, 5, and 6 in
control, 4, and 16 groups, respectively; *P < 0.05 vs. control group;
†P < 0.05 vs. basal period).
TABLE 1
Arterial plasma NEFA, blood glycerol, and -hydroxybutyrate levels (mol/l) and net hepatic balances (mol  kg
1  min
1) in 60-h fasted
conscious canines during the basal (40 to 0 min) and experimental (0–300 min) periods
Basal
period
Experimental period (min)
30 60 120 180 240 300
Plasma NEFA level (mol/l)
Control 863  110 613  121† 579  121† 656  121† 656  74† 734  121† 688  118†
4 Basal Ins 813  134 345  66*† 179  43*† 169  43*† 148  25*† 151  35*† 99  26*†
16 Basal Ins 1,151  54* 287  61*† 159  42*† 116  33*† 71  26*† 74  38*† 63  37*†
Net hepatic NEFA uptake
(mol  kg
1  min
1)
Control 1.9  0.5 1.7  0.4 1.6  0.4 1.8  0.4 2.1  0.4 1.4  0.5 1.2  0.3
4 Basal Ins 2.2  0.6 0.9  0.3*† 0.4  0.2*† 0.5  0.3*† 0.2  0.2*† 0.4  0.1*† 0.3  0.2*†
16 Basal Ins 3.1  0.5 0.6  0.2*† 0.4  0.2*† 0.2  0.1*† 0.2  0.1*† 0.2  0.1*† 0.1  0.1*†
Plasma glycerol level (mol/l)
Control 68  13 58  12 54  66 0  96 0  86 5  10 57  10
4 Basal Ins 88  14 48  11† 49  16† 51  18† 49  15† 58  24† 46  10†
16 Basal Ins 103  85 9  11† 45  10† 42  8† 31  4† 33  11† 38  10†
Net hepatic glycerol uptake
(mol  kg
1  min
1)
Control 1.8  0.3 1.2  0.4 1.2  0.2 1.1  0.3 1.3  0.3 1.2  0.4 1.4  0.3
4 Basal Ins 1.3  0.3 0.6  0.1† 0.7  0.2 0.8  0.3 0.7  0.2 0.8  0.3 0.8  0.3
16 Basal Ins 1.9  0.4 0.9  0.3† 0.7  0.3† 0.8  0.2† 0.5  0.1† 0.5  0.1† 0.7  0.1†
Plasma -hydroxybutyrate
level (mol/l)
Control 72  18 51  16 47  16 51  19 61  21 58  16 65  16
4 Basal Ins 75  28 26  6† 14  1† 12  2*† 12  2*† 12  2*† 14  2*†
16 Basal Ins 79  17 21  4† 14  2† 10  2*† 10  3*† 8  2*† 11  3*†
Net hepatic -hydroxybutyrate
output (mol  kg
1  min
1)
Control 2.3  0.5 1.5  0.5 1.1  0.4 1.4  0.5 1.4  0.4 1.5  0.4 1.5  0.4
4 Basal Ins 1.6  0.8 0.4  0.3*† 0.1  0.1† 0.1  0.1*† 0.1  0.0*† 0.1  0.1*† 0.0  0.0*†
16 Basal Ins 2.7  0.7 0.4  0.2*† 0.0  0.1† 0.1  0.1*† 0.0  0.0*† 0.0  0.0*† 0.0  0.0*†
Data are means  SEM; n  5, 5, and 6 in the control, 4, and 16 insulin (Ins) groups, respectively; *P  0.05 vs. control group; †P  0.05
vs. basal period. Somatostatin and portal insulin and glucagon were infused at 0 min to control hormone levels, and glucose was infused to
maintain euglycemia.
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time (Table 2). There were rapid and sustained decreases
in the NHFX of lactate in the 4 and 16 groups (240 and
50%, respectively, at 30 min) that persisted until the end of
the study. Arterial lactate levels tended to rise in the 4
group and increased even more substantially in the 16
group (116 and 84%, respectively, by the last hour).
Therefore, as a result of these somewhat offsetting effects,
net hepatic lactate uptake was reduced by 
50% (3t o
4 mol  kg
1  min
1) at 30 min in both groups but was
TABLE 2
Arterial blood lactate, alanine, and GNG amino acid (alanine, serine, glycine, threonine, glutamate, and glutamine) levels (mol/l), net
hepatic fractional extraction and uptake rates (mol  kg
1  min
1), and GNG precursor uptake (mg  kg
1  min
1) in 60-h fasted
conscious canines during the basal (40 to 0 min) and experimental (0–300 min) periods
Basal
period
Experimental period (min)
30 60 120 180 240 300
Blood lactate level (mol/l)
Control 409  103 488  122 425  126 429  134 422  121 399  96 352  71
4 Basal Ins 474  121 447  82 539  93 480  107 483  122 545  124 555  107
16 Basal Ins 393  49 513  59 776  107*† 849  180*† 744  127† 741  85† 705  49*†
Net hepatic lactate
fractional extraction
Control 0.49  0.06 0.52  0.09 0.50  0.08 0.50  0.07 0.56  0.10 0.56  0.05 0.56  0.04
4 Basal Ins 0.47  0.10 0.28  0.16* 0.15  0.12*† 0.27  0.06* 0.30  0.06* 0.32  0.06* 0.25  0.01*
16 Basal Ins 0.59  0.04 0.28  0.13*† 0.24  0.12*† 0.22  0.03*† 0.29  0.03*† 0.27  0.04*† 0.32  0.04*†
Net hepatic lactate uptake
(mol  kg
1  min
1)
Control 7.5  0.9 7.2  1.0 6.3  0.4 6.7  0.7 6.7  0.6 7.7  1.0 7.3  0.7
4 Basal Ins 6.3  1.4 3.3  1.8 1.6  1.4*† 3.4  0.8 3.8  0.3 4.4  0.8 4.1  0.9
16 Basal Ins 8.0  1.7 3.6  1.8*† 3.8  1.6† 5.0  1.7 6.2  1.9 5.6  1.4 6.7  1.5
Blood alanine level
(mol/l)
Control 255  33 256  31 243  36 225  39 219  26 228  22 233  24
4 Basal Ins 275  44 262  26 248  16 203  17† 175  18† 179  22† 164  24*†
16 Basal Ins 266  16 232  14† 231  12† 192  18† 167  16† 141  13*† 129  10*†
Net hepatic alanine
fractional extraction
Control 0.24  0.04 0.24  0.03 0.32  0.03 0.37  0.02† 0.37  0.03† 0.33  0.03 0.30  0.05
4 Basal Ins 0.28  0.04 0.34  0.03 0.37  0.03 0.45  0.02† 0.46  0.02*† 0.42  0.02*† 0.46  0.04*†
16 Basal Ins 0.33  0.03 0.34  0.04 0.41  0.04 0.39  0.04 0.46  0.02† 0.45  0.03*† 0.46  0.03*†
Net hepatic alanine uptake
(mol  kg
1  min
1)
Control 2.6  0.07 2.2  0.5 2.6  0.4 2.7  0.4 2.4  0.1 2.6  0.3 2.5  0.5
4 Basal Ins 2.6  0.7 2.5  0.5 2.5  0.3 2.6  0.4 2.5  0.4 2.3  0.4 2.5  0.6
16 Basal Ins 3.0  0.5 2.2  0.4 2.3  0.2 2.1  0.3 2.3  0.2 2.0  0.2 1.9  0.2
Blood GNG amino acid
level (mol/l)
Control 1,884  161 1,810  125 1,728  142† 1,591  133† 1,581  123† 1,632  116† 1,536  171†
4 Basal Ins 1,839  87 1,754  78 1,536  58† 1,336  76† 1,199  69*† 1,199  91*† 1,170  118*†
16 Basal Ins 1,575  60 1,460  89 1,247  79*† 1,072  51*† 995  45*† 915  72*† 852  55*†
Net hepatic GNG amino
acid fractional
extraction
Control 0.07  0.02 0.09  0.02 0.14  0.02 0.15  0.03 0.17  0.03† 0.14  0.03 0.16  0.04†
4 Basal Ins 0.08  0.01 0.15  0.02† 0.17  0.03† 0.20  0.01† 0.15  0.02† 0.20  0.02† 0.20  0.01†
16 Basal Ins 0.14  0.03 0.15  0.03 0.11  0.03 0.12  0.02 0.17  0.02 0.15  0.01 0.15  0.03
Net hepatic GNG amino
acid uptake (mol 
kg
1  min
1)
Control 5.5  2.3 5.1  1.7 6.4  1.2 6.3  1.2 7.2  1.5 6.1  1.2 7.6  0.8
4 Basal Ins 4.3  1.0 6.2  0.5 6.3  0.9 6.6  0.3 4.9  1.0 5.9  1.1 6.0  1.1
16 Basal Ins 5.6  1.0 4.9  1.0 3.5  0.4 3.2  0.4* 3.8  0.4* 3.2  0.4 3.0  0.4*
GNG precursor uptake in
glucose equivalents
(mg  kg
1  min
1)
Control 1.4  0.3 1.3  0.2 1.3  0.1 1.3  0.1 1.4  0.1 1.4  0.1 1.5  0.1
4 Basal Ins 1.1  0.2 1.0  0.2 0.8  0.1 1.0  0.1 0.9  0.1 1.0  0.2 1.0  0.2
16 Basal Ins 1.5  0.3 0.9  0.2† 0.8  0.1† 0.9  0.2† 1.0  0.2† 0.9  0.1† 1.0  0.1†
Data are means  SEM; n  5, 5, and 6 in the control, 4, and 16 groups, respectively; *P  0.05 vs. control group; †P  0.05 vs.
basal period. Somatostatin and portal insulin and glucagon were infused at 0 min to control hormone levels, and glucose was infused
to maintain euglycemia.
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hour.
Net hepatic glycerol uptake fell rapidly (231, 57, and
54% [0.7 to 1 mol  kg
1  min
1) by 30 min in the
control, 4, and 16 groups, respectively, in parallel with
changes in glycerol availability (Table 1). By the last hour
of the study, rates of net hepatic glycerol uptake were
reduced by 25, 42, and 68%, respectively.
In the control and 4 groups, there were decreases in
blood alanine level that offset increases in alanine NHFX
so that net hepatic alanine uptake did not change signiﬁ-
cantly over time (Table 3). In the 16 group, there was a
progressive decrease in the alanine level (250% by the end
of the study), but the NHFX of alanine did not increase
enough to offset this fall; therefore, net hepatic alanine
uptake was reduced by one-third during the last hour of
the study. The average summed GNG amino acid (alanine,
serine, glycine, threonine, glutamate, and glutamine)
levels followed a similar pattern of decline as alanine
(reduced by 16, 36, and 44% in the control, 4, and 16
groups, respectively) (Table 2). The NHFX of GNG
amino acids increased from basal in the control and 4
groups (2.1- and 2.4-fold, respectively, during the last
hour) but did not change in the 16 group. As a result,
net hepatic GNG amino acid uptake increased by 26 and
38% (1.4–1.7 mol  kg
1  min
1) in the control and 4
groups, respectively, whereas in the 16 group there
was a slow decline (244% by the last hour; 2.5 mol 
kg
1  min
1) that paralleled amino acid availability.
Liver and nonhepatic glucose ﬂuxes. Net hepatic glu-
cose output (NHGO) was similar during the basal period in
the three groups (1.6–2.0 mg  kg
1  min
1; Fig. 2). By the
last hour, NHGO was 1.3  0.2 mg  kg
1  min
1 in the
control group. In the 4 and 16 groups, hyperinsulin-
emia had suppressed NHGO by 50% at 30 min and by the
last hour had switched the liver to net hepatic glucose
uptake (0.2  0.1 and 0.9  0.3 mg  kg
1  min
1,
respectively). Euglycemia was maintained by glucose in-
fusion (reaching 0.5  0.2, 6.6  1.0, and 15.5  1.5 mg 
kg
1  min
1 in the control, 4, and 16 groups, respec-
tively, during the last hour; Table 3). The majority of the
increase in glucose requirement in the 4 and 16 groups
related to increases in muscle glucose uptake (nonhepatic
glucose uptake was 1.8  0.3, 6.4  1, and 14.7  1.6 mg 
kg
1  min
1, respectively, during the last hour; Table 3).
GNG and glycogenolytic ﬂux rates. GNG ﬂux to G6P
did not change from basal in the control and 4 groups,
whereas in the 16 group there was a rapid (30 min) and
sustained decrease (235%; 0.5 mg  kg
1  min
1; Table
2; Fig. 3). In the control group, net hepatic glycogenolysis
decreased over time until it was almost completely inhib-
ited by the end of the experiment. Net hepatic glycogen-
olysis decreased more rapidly in the 4 and 16 groups,
and by the last hour of the study the liver had switched to
net hepatic glycogen deposition (1.0  0.2 and 1.5  0.2
mg  kg
1  min
1, respectively; Fig. 3).
Molecular effects of insulin. The effects of insulin
treatment on targets of insulin receptor signaling were
assessed in biopsies taken at the end of each experiment.
Akt, a marker of activation of the phosphatidylinositol 3
kinase insulin-signaling pathway, was similarly activated
in both the 4 and 16 groups, with the ratio of phos-
TABLE 3
Glucose infusion rate and nonhepatic glucose uptake in 60-h fasted conscious canines during the basal (40 to 0 min) and
experimental (0–300 min) periods
Basal
period
Experimental period (min)
30 60 120 180 240 300
Glucose infusion rate
(mg  kg
1  min
1)
Control 0.0  0.0 0.0  0.0 0.0  0.0 0.1  0.1 0.3  0.1 0.6  0.3 0.5  0.2
4 Basal Ins 0.0  0.0 0.7  0.1 2.7  0.6*† 4.1  1.0*† 4.9  1.0*† 6.1  0.9*† 7.2  1.2*†
16 Basal Ins 0.0  0.0 3.2  1.1*† 7.5  1.2*† 11.7  1.4*† 12.5  1.1*† 14.5  1.3*† 16.6  1.7*†
Nonhepatic glucose uptake
(mg  kg
1  min
1)
Control 1.8  0.3 1.9  0.3 1.5  0.2 1.6  0.2 1.5  0.2 1.8  0.4 1.7  0.3
4 Basal Ins 1.6  0.2 1.9  0.3 3.1  0.6 4.6  0.9*† 5.0  0.9*† 6.3  0.9*† 6.4  1.2*†
16 Basal Ins 2.0  0.3 4.5  1.3*† 7.9  1.4*† 11.4  1.4*† 12.0  1.4*† 13.8  1.6*† 15.7  1.8*†
Data are means  SEM; n  5, 5, and 6 in the control, 4, and 16 groups, respectively; *P  0.05 vs. control group; †P  0.05 vs. basal
period. Somatostatin and portal insulin and glucagon were infused at 0 min to control hormone levels, and glucose was infused to maintain
euglycemia.
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4.5-fold, respectively, compared with the control group
(Fig. 4A). In line with the changes in glycogen ﬂux, the
ratio of P-Ser9 glycogen synthase kinase 3 (GSK-3)t o
total GSK-3 increased 2.3- and 2.2-fold in the 4 and 16
groups, respectively, compared with control, and the ratio
of P-Ser21 GSK-3 to total GSK-3 increased 2.8- and
3.4-fold, respectively (Fig. 4B). The ratio of P-Ser256
FOXO1 to total FOXO1 (a transcription factor involved in
the regulation of GNG enzymes, including G6Pase and
PEPCK) increased 3.0- and 3.6-fold in the 4 and 16
groups, respectively (Fig. 4C), and analysis of total FOXO1
levels in nuclear-enriched fractions detected reductions of
84 and 85%, respectively, compared with the control group
(Fig. 4C). Although there were no signiﬁcant differences
between the 4 and 16 groups for Akt, GSK-3, or FOXO1
phosphorylation, activation in the 16 group always
tended to be slightly greater compared with the 4 group.
G6Pase and glucokinase serve as “gatekeepers” for
hepatic glucose uptake and release. G6Pase mRNA expres-
sion was decreased by 60 and 80% in the 4 and 16
groups, respectively, compared with the control group
(Fig. 4D). Both glucokinase mRNA and protein expression
increased in a stepwise manner with increasing hyperin-
sulinemia: mRNA levels increased 8.8- and 13.7-fold,
whereas protein levels in cytoplasmic-enriched fractions
increased 1.9- and 2.6-fold, respectively (Fig. 4E and F).
Analysis of GNG markers revealed that hyperinsulinemia
decreased PEPCK mRNA and protein levels by 90 and 60%,
respectively, with no differences between the 4 and 16
groups (Fig. 4G and H). Hepatic STAT3 phosphorylation
(shown to be activated in the liver in response to central
insulin action [12]) was increased 3.5- and 5.2-fold,
respectively.
F2,6P2 is a regulator of the glycolytic and GNG path-
ways, and pyruvate kinase catalyzes the conversion of
phosphoenolpyruvate into pyruvate. At the end of the
study, the hepatic concentrations of F2,6P2 were 4.6  1.1,
11.6  1.7, and 26.9  3.3 nmol/g in the control, 4, and
16 groups, respectively (Table 4). Pyruvate kinase activ-
ities were 0.46  0.06, 0.70  0.09, and 0.82  0.08
units/mg protein, respectively (Table 4).
DISCUSSION
The in vivo regulation of GNG ﬂux by insulin is complex
and not fully understood. In this study, conditions were
optimized to increase the likelihood of observing an acute
effect of insulin on the process. Canines were fasted for
60 h to enhance gluconeogenesis, insulin was elevated for
5 h to allow sufﬁcient time for transcriptional and transla-
tional changes to occur, and two insulin doses were
administered (the highest of which produced a maximal
physiologic level). In agreement with previous studies
(20,26), GNG ﬂux to G6P did not change signiﬁcantly over
time in the control or 4 groups. At the highest level of
insulin, however, GNG ﬂux to G6P was reduced, but only
by one-third. Further, this change occurred rapidly (within
30 min), presumably before an insulin-induced decrease in
PEPCK activity was possible. Thereafter, no further
change in GNG ﬂux occurred, despite an eventual marked
decrease in PEPCK protein.
As expected, insulin signaling pathways were activated
with hyperinsulinemia, as indicated by increased phos-
phorylation of Akt, GSK-3, and FOXO1. The balance be-
tween the activities of G6Pase and glucokinase determines
glucose ﬂux into and out of the liver. Insulin reduced
G6Pase mRNA (and presumably the protein level) and
increased glucokinase mRNA and glucokinase protein
levels so that the ratio of G6Pase to glucokinase expres-
sion in the three groups corresponded inversely with
circulating insulin levels, reﬂecting the shift toward net
hepatic glucose uptake.
Net hepatic glycogenolysis accounted for one-third of
the glucose produced by the liver in the basal period
(versus two-thirds after an 18-h fast [1]), in agreement with
previous ﬁndings in 66-h fasted canines in which glycogen-
olysis was estimated to account for 41% of basal HGP
using an independent technique and 23% using the A-V
difference method (25). The decrease in HGP that oc-
curred during hyperinsulinemia in the present study was
due primarily to reduced net glycogenolysis. Insulin in-
creased the phosphorylation of GSK-3, thereby inactivat-
ing it and facilitating activation of glycogen synthase (27).
The rapid effect on glycogen metabolism occurred in a
dose-dependent manner, such that net glycogen synthesis
was clearly evident after5ho fhyperinsulinemia (2.5 mg 
kg
1  min
1) in the 16 group, even under euglycemic
conditions. In the control group, an insulin infusion rate
that was only modestly (
40%) above the basal endoge-
nous insulin secretion rate (21) completely eliminated net
glycogen breakdown by 5 h, demonstrating the exquisite
sensitivity of liver glycogen metabolism to small incre-
ments in insulin.
GNG ﬂux to G6P was rapidly reduced in the 16 group,
decreasing near maximally by 30 min, although the effect
was modest ( from baseline 0.5 mg  kg
1  min
1). This
initial decrease was primarily the result of a fall in net
hepatic lactate uptake and was associated with the insulin-
induced inhibition of lipolysis. Human (28,29) and canine
(30) experiments have shown that plasma NEFAs stimu-
late hepatic gluconeogenesis and that a fall in circulating
NEFAs causes a redirection of carbon ﬂow within the liver
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results from increased glycolytic ﬂux through PFK-1 due
to reduced inhibition of the enzyme by citrate, a product of
fat oxidation (4,8). In the present study, hyperinsulinemia
led to robust, rapid, and dose-dependent effects on fat
metabolism (75% reduction in NEFA levels and net hepatic
uptake, and almost complete inhibition of hepatic fat
oxidation in the 16 group at 30 min). In addition to
NEFA-mediated effects, the rapid effect of insulin on GNG
ﬂux to G6P was also probably explained by allosteric and
covalent regulation of GNG and glycolytic enzymes. Insu-
lin stimulates dephosphorylation of the bifunctional
enzyme, activating the kinase and inactivating the phos-
phatase, thereby increasing F2,6P2 (4,8). This leads to
increased glycolytic ﬂux through PFK-1 and to a lesser
degree decreased GNG ﬂux through fructose 1,6-bisphos-
phatase (4,8). In addition, insulin activates pyruvate kinase
by cAMP-dependent and -independent mechanisms and
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creased lactate formation from pyruvate. Indeed, in the 4
and 16 groups, respectively, we observed 2.5- and 5.8-
fold increases in F2,6P2 and 1.5- and 1.8-fold elevations in
pyruvate kinase activity, although the time course of these
changes is not known. Thus, the rapid decrease in GNG
ﬂux to G6P, and in particular net lactate uptake, which can
be explained by the direct and indirect effects of insulin.
The hepatic GNG precursor load and extraction are
also determinants of GNG ﬂux. In the 4 and 16
groups, inhibition of lipolysis resulted in decreased
glycerol levels, and therefore the contribution of glyc-
erol to GNG ﬂux decreased. The inhibition of net
hepatic lactate fractional extraction remained constant
during hyperinsulinemia (
50%); however, circulating
lactate levels increased, especially in the 16 group
(185%), as a result of reduced liver lactate uptake (32)
and increased muscle and fat lactate production (33,34).
Net hepatic GNG amino acid fractional extraction in-
creased quickly in the 4 group, to nearly twice the
basal rate at 30 min, most likely due to insulin stimula-
tion of hepatic amino acid transport (35). Therefore,
despite decreased amino acid availability (probably due
to reduced muscle protein turnover [10]), net hepatic
GNG amino acid uptake increased enough to offset the
reductions in net lactate and glycerol uptake in the 4
group, and thus GNG ﬂux did not change. In the 16
group, although hepatic extraction of alanine increased
by 40% during hyperinsulinemia, a collective increase in
GNG amino acid fractional extraction did not occur.
Thus, decreased net hepatic uptake of lactate, glycerol,
and GNG amino acids all contributed to the fall in GNG
ﬂux in this group. The fall in lactate uptake predomi-
nated early, whereas reduced amino acid uptake be-
came more important by the end of the study.
PEPCK is considered to be a key GNG enzyme, and its
mRNA levels are frequently used as an index of glucone-
ogenesis. PEPCK mRNA and protein expression were
measured at the end of the study to determine their
correspondence with GNG ﬂux. Despite marked and equal
suppression of PEPCK by insulin in the 4 and 16
groups (mRNA decreased by 90% and protein by 60%),
GNG ﬂux did not change in the 4 group, and there was
only a 33% decrease in the 16 group. In addition, inhibi-
tion of GNG ﬂux in the 16 group occurred within 30 min
of the rise in insulin, and the degree of inhibition remained
unchanged over the subsequent 4.5 h of hyperinsulinemia.
Although PEPCK transcription can be reduced by insulin
in vitro within minutes (36,37), the enzyme’s activity is
determined by its protein levels, which change much more
slowly. Therefore, a decrease in PEPCK activity is unlikely
to explain the rapid changes in GNG ﬂux that we observed.
Thus, although PEPCK transcription and translation were
clearly regulated by insulin, the enzyme did not appear to
be rate limiting for gluconeogenesis. Some studies in rats
have demonstrated control of gluconeogenesis and glu-
cose production via inhibition of PEPCK with 3-mercap-
topicolinate (38,39), and it has been concluded that
PEPCK is the rate-controlling enzyme for gluconeogenesis
(40). On the other hand, studies using metabolic control
analysis in isolated hepatocytes have suggested that a
number of enzymes play important roles in controlling
GNG ﬂux and that PEPCK displays weak control strength
(41–43). Our results agree with those from studies in
transgenic mice where a 70% reduction in PEPCK content
resulted in only a 20% reduction in GNG ﬂux (44) and from
a very recent study in patients with type 2 diabetes where
increased transcriptional expression of PEPCK did not
account for increased gluconeogenesis (45). Thus, at least
in canines and humans, PEPCK appears to contribute little
to the hormonal regulation of gluconeogenesis.
Insulin action in the hypothalamus may also control
hepatic gluconeogenesis (12–14), although this has been
demonstrated only in rodents. Activation of brain insulin
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FIG. 4. Continued.
TABLE 4
Hepatic F2,6P2 levels and pyruvate kinase activities at the end of
the study in 60-h fasted conscious canines
Control
group 4 group 16 group
F2,6P2 (nmol/g) 4.6  1.1 11.6  1.7* 26.9  3.3*
Pyruvate kinase activity
(U/mg protein) 0.46  0.06 0.70  0.09* 0.82  0.08*
Data are means  SEM; n  5, 5, and 6 in the control, 4, and 16
groups, respectively; *P  0.05 vs. control group. Somatostatin and
portal insulin and glucagon were infused at 0 min to control hormone
levels and glucose was infused to maintain euglycemia.
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ylation, resulting in inhibition of PEPCK and G6Pase
transcription in mice (12). In the present study, insulin
increased phosphorylation of STAT3 in the liver in a
dose-dependent fashion, but the time course of the activa-
tion is not known. We cannot say whether insulin action in
the brain was partially responsible for the observed
changes in PEPCK because the insulin levels in the liver
itself rose markedly. Nevertheless, using the same logic as
noted above, it is unlikely that a STAT3-mediated change
in the activity of the GNG enzymes had any effect on GNG
ﬂux to G6P.
In summary, this study demonstrates that a large, but still
physiologic, rise in plasma insulin can reduce GNG ﬂux to
G6P acutely in the conscious canine. However, this effect
required a near-maximal physiological level of the hormone
and was modest compared with the effect on glycogenolysis,
even in 60-h fasted animals. The decrease in GNG ﬂux
occurred within 30 min and was associated with marked
inhibition of hepatic fat oxidation, increases in hepatic
F2,6P2 level and pyruvate kinase activity, and reductions in
hepatic lactate, glycerol, and amino acid extraction. No
further diminution in GNG ﬂux occurred over the remaining
4.5 h of the study, despite a marked decrease in PEPCK
content, suggesting poor control strength for this enzyme in
GNG regulation in canines.
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